Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2010 Aug 10;9(10):2793–2802. doi: 10.1158/1535-7163.MCT-10-0477

Figure 2.

Figure 2

Western analysis showing that CXCL9-11 are down modulated at day 3 of therapy (D3) with sorafenib or sunitinib and at the time of resistance (R) as compared to untreated tumors (un). Results from 2–3 representative tumors harvested from different mice treated with the described conditions are shown.